Our test menu has expanded, again! This month, we have added 11 new Spotlight™ panels, three new Focus™ panels, and one new Comprehensive panel, across multiple disorder types.
This month, we are happy to announce we have added another 11 tests to our growing catalog of Courtagen Spotlight™ Panels. These small (3 to 50 genes) panels provide clinicians with a targeted approach to genetic testing, and are best used when a patient's symptomatology is discernible. Each Spotlight Panel contains addresses a group of disorders with overlapping symptoms, making test selection clear and straightforward.
We are happy to announce the addition of 10 new tests to our Spotlight™ Panel line, which provides clinicians a targeted approach to genetic testing when a patient's symptomatology is discernible. Each Spotlight Panel contains between approximately 3 to 50 genes selected to address a group of disorders with overlapping symptoms, making test selection clear and straightforward.
We are excited to announce that we received a Notice of Allowance from the United States Patent and Trademark Office for a patent that uses a personalized medicine approach to match genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol.
We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.
Earlier this week, voters in four states (Arkansas, Florida, Montana, and North Dakota) approved legislation that made medicinal marijuana legal in their respective states. Now more than half the states have approved medical marijuana in some form. It’s fitting that this landmark was reached in the month of November, which happens to be Epilepsy Awareness month.
Last week we packed up our computers, sequencers, pipettes, and numerous test tubes filled with saliva to move down the road to our new headquarters at 8 Cabot Road Woburn, MA.
Topics: Company News
Courtagen is excited to announce that it has partnered with the United Mitochondrial Disease Foundation as part of a new pilot program designed to expand access to genetic testing for patients with mitochondrial disorders who have been unable to access testing due to financial barriers.
Topics: Courtagen Gives Back